Veritas In Silico Inc. (JP:130A) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Veritas In Silico Inc. is expanding its global reach by securing a patent in Europe for its innovative method in RNA-targeted drug discovery. This strategic move is expected to enhance their proprietary drug discovery platform, ibVIS®, despite the patent having a minimal immediate impact on business performance. The company anticipates significant future progress from this development.
For further insights into JP:130A stock, check out TipRanks’ Stock Analysis page.